Health/Medical: Novagali Pharma announces the launch of Cationorm

- The Innovative Cationic Emulsion for the Treatment of Dry Eye Symptoms
- An optimal Solution for Patients
- The First Product Developed From its Pipeline to be Marketed

Evry (ANTARA News/PRNewswire-AsiaNet) - Novagali Pharma, an ophthalmic specialty pharmaceutical company announces the commercial launch in France of its first product Cationorm(R). This cationic emulsion is an innovative approach to treat dry eye symptoms. It has been developed on the basis of Novagali Pharma patented technology platform Novasorb(R).

Dry eye syndrome is the second cause of consultation in ophthalmology. It concerns over 100 million people in the world and 14% of the adults of more than 40 years. Due to a chronic lack of lubrication and moisture in the eye, its consequences range from irritation to ocular inflammation of the conjunctiva and corneal tissues of the eyes. People with dry eye have sandy-gritty irritation or burning in their eyes. In most severe cases, corneal lesions may lead to vision loss. Specific factors such as ageing populations, pollution, air conditioning, extended use of computers, contribute to an increase in the prevalence of the syndrome and in opportunities for the development of more efficient products.

Cationorm(R) brings a true innovation to the patients suffering from dry eye symptoms. The cationic emulsion reproduces the tear mechanisms of action to act on the different levels of the tear film. Cationorm(R) uniquely combines lubricating and hydrating properties, optimal spreading on the surface of the eye, replenishment of the tear film lipid layer and prevention of tear evaporation. The results of clinical study have clearly demonstrated Cationorm(R) advantages for patients: tolerance, long-lasting relief and optimal comfort.

These advantages are based on Novasorb(R), the proprietary cationic emulsion technology platform of Novagali Pharma.

Novasorb(R) is designed to improve topical administration of ophthalmic medicines. It is based on the electrostatic attraction that occurs between the droplets of a positively-charged emulsion and the negatively charged cells of the ocular surface, including cornea and conjunctiva.

The commercial launch of Cationorm(R) in Europe and in the United States by the end 2008, where the product complies with the OTC status, is a major event for the development of Novagali Pharma. "Cationorm(R) commercial launch is very special to us being our first marketed product coming out of our pipeline. It is the result of many years of work for the entire Novagali team and we are very proud of the innovation Cationorm(R) brings for the treatment of dry eye symptoms," said Jerome Martinez, CEO of Novagali Pharma.

Cationorm(R) is a medical device available in France since April 2008. The product is unpreserved and packaged in box of 30 sterile single vials.

About Novagali Pharma : http://www.novagali.com

Novagali Pharma is an ophthalmic pharmaceutical company based in the Genopole biocluster in Evry (France) that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cyclokat(R), a product for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma has 50 employees.

SOURCE: Novagali Pharma
CONTACT: Presse,
Novagali Pharma,
VP RH & Communication,
Genevieve Garrigos,
+33-6-65-54-60-19,
Ariane Pretre,
genevieve.garrigos@novagali.com;
Euro RSCG,
+33-6-81-37-72-48,
ariane.pretre@eurorscg.fr;
C&O Euro RSCG C&O,
Emilie Dhelens,
+33-1-58-47-95-62,
emilie.dhelens@eurorscg.fr
Web site: http://www.novagali.com

COPYRIGHT © 2008

BioReliance expands operations in Asia Pacific region

Rockville, Md. (BUSINESS WIRE) - BioReliance Corporation announced today it has established a commercial office in Tokyo, expanding its operations to significantly address the growth opportunities in the Asia Pacific markets. BioReliance Corporation is a leading contract services company that provides biologics safety testing, toxicology, viral manufacturing and laboratory animal diagnostic services to the pharmaceutical and biopharmaceutical industries worldwide.

"With an established and growing business already in Japan and other Asian Pacific countries, BioReliance has served this region successfully for many years," said David A. Dodd, President, CEO and Chairman of BioReliance Corporation.
"However, as these markets continue to flourish, we believe that, with a full-time and expanding presence, we can more rapidly serve the needs of our pharmaceutical/biopharmaceutical clients in this region, while increasing new business relationships.""Locating in Tokyo will provide a strategic advantage for BioReliance," said Dave Bellitt, Vice President, Global Commercial Operations ? Biologics. "With the experienced team we are assembling, we will be able to deliver the highest quality, on-time portfolio of biosafety services to the rapidly developing pharmaceutical and biopharmaceutical research industry in this region. Our immediate goal is to complete staffing and pursue new clients aggressively.

Long-term, we are committed to increasing our global leadership position by further expansion and growth in this region."About BioReliance BioReliance Corporation is a leading specialist provider of cost-effective contract services to the pharmaceutical and biopharmaceutical industries, offering more than 1,000 tests or services related to biologics safety testing, in vitro and in vivo toxicology, viral manufacturing, GMP manufacturing, pre-clinical testing and lab animal health diagnostics. Founded in 1947 as Microbiological Associates, BioReliance is headquartered in Rockville, Maryland, and has primary facilities in Rockville, Glasgow, Scotland and Stirling, Scotland, and employs more than 700 people globally.
For more information, visit www.bioreliance.com.

BioReliance Corporation
David Walker, 301-610-2866 Vice President & Chief Financial Officer
OR
Parallax Communications Group
Scott Litherland, 317-638-7898
slitherland@parallaxgroup.net

Anadis licenses antibody technologies from ImmuCell

Melbourne, Australia - (BUSINESS WIRE) - Anadis Limited (ASX: ANX), an Australian-based biotechnology company focused on milk derived polyclonal antibodies and other milk-derived bioactives, announced today that it had signed a final agreement with ImmuCell Corporation (NASDAQ Capital Market: ICCC), a biotechnology company headquartered in Portland, Maine, USA.

Under the agreement, Anadis has licensed from ImmuCell a portfolio of issued patents, IND filings, clinical data, manufacturing plans and know-how related to several human heath product lines. In particular the deal will directly enhance product development work for Clostridium difficile, E.coli and immune deficiency related opportunistic infections. The licensed technologies are all related to the usage of hyperimmune bovine colostrum to provide immediate-acting passive immunity against infectious diseases. The royalty-based deal requires no upfront or milestone payments.

The intellectual property Anadis obtains under this agreement includes two issued U.S. patents, US Pat. No. 5,773,000 (Therapeutic treatment of Clostridium difficile-associated diseases) and US Pat.

No. 6,074,689 (Colonic delivery of protein or peptide compositions) which is applicable to a broad range of indications Anadis is pursuing using its bovine colostrum antibodies and bioactives.

Dr. Zeil Rosenberg, Anadis' CEO stated, "Beyond the issued patents, the clinical work that ImmuCell has successfully completed over many years with the U.S. Navy and Johns Hopkins University and others will expedite Anadis commercial product development to address large unmet human health needs in the US and worldwide. Having better clinical data strengthens our
ability to collaborate with pharmaceutical companies as we begin entering the US market with our product portfolio.
"Clostridium difficile or "C.diff" infection is a serious gastrointestinal bacterial and nosocomial (hospital acquired) disease among hospitalized patients worldwide. The licensed technology includes successful results from a U.S. phase II clinical study conducted by ImmuCell. C. difficile bacteria infection accounts for considerable increases in the length of hospital stays and more than $1.1 billion in health care costs each year in the United States. The bacteria infection is a common cause of significant morbidity and even death in elderly or debilitated patients (American Family Physician, 2005).The licensing arrangement will expedite Anadis' clinical trials under its Immuron joint venture with Hadassah Medical Center, Israel.

Diarrhea-related illnesses represent an important clinical target for both the military and for public health. Leveraging significant and positive clinical trial data under this agreement, Anadis intends to maintain close collaboration with the US Department of Defense and other research institutions in its efforts to develop an acceptable immediate-acting product to reduce risk from infectious diarrhea-related diseases. Such products would have a large and worldwide market.

Anadis will provide ImmuCell with access to manufacturing infrastructure and know-how for their veterinary applications, enhancing ImmuCell's ability to introduce its own veterinary products into Australia and New Zealand. Anadis shall receive a royalty on sales that are marketed under ImmuCell's own name that are produced under this collaboration in Australia. Such marketable products for the veterinary market are expected to be launched within two years.

About Anadis (www.anadis.com): Anadis Limited (ASX: ANX, OTC:ANDIY) is a biopharmaceutical company producing antibodies and other bioactive proteins as health products.

Its all-natural, orally administered and colostrum-derived platform is proven safe and effective, with regulatory classification as GRAS (Generally Regarded as Safe) and BSE-free certification, allowing for rapid progression from concept to market. The company's core technology relies on advanced dairy industry processing methods including immunization of pregnant cows with proprietary antigen specific vaccines, which in turn elicit an immune response by the cow.

First-milking colostrum contains more than 35% immunoglobulin and this targeted antibody, along with other immune system bioactive nutrients, is subsequently harvested, fractionated and freeze dried under the highest dairy industry standards. The company is addressing a variety of unmet human health needs with broad market demand, including: Oral and GI Mucositis; Inflammatory Bowel Disease (IBD); Irritable Bowel Syndrome (IBS); Travellers' Diarrhea; Influenza and Rotavirus.
The company operates from Melbourne, Australia and New York City.

Anadis LimitedCEODr. Zeil Rosenberg, +1 646-402-5289
zeil@anadis.com or VP of Business DevelopmentDr. Oren Fuerst,
+1?646-259-3321 or en@anadis.com or Investor RelationsArie
Nudel, +61 3 9358 6388 arie.n@anadis.com.au

Wyeth to invest $280 million to build state-of-the-art facility

Madison, New Jersey and Suzhou (ANTARA News/PRNewswire-AsiaNet) - Wyeth (NYSE: WYE) announced today that it is investing $280 million to build a state-of-the-art nutritional manufacturing facility in Suzhou Industrial Park, Jiangsu Province, China.

The new facility will primarily produce infant formula milk powder and other nutritional products. When completed, the site will be one of the world's largest nutritional manufacturing facilities.

"This investment reflects Wyeth's long-term commitment to pediatric nutrition, as well as the recognition that China is now the fastest-growing market for Wyeth's worldwide nutritional business. When completed, this facility will enable us to meet the growing demand for nutritional products in the Chinese market," said Robert Essner, Wyeth's Chairman of the Board.

"A key element of our Company's mission is ensuring that infants and children have access to the best and highest-quality products. This site will help us achieve this objective."

The new facility will become part of Wyeth's global nutritional manufacturing and supply network and will feature state-of-the-art technology for manufacturing milk powder for infants and young children.

Construction at the site started this month, and the plant is scheduled to be operational by late 2010. At full operation, the plant is expected to employ about 500 employees. Products made at this facility will primarily supply the local market.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

These risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products, including with respect to our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS."

The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
For more information, visit www.Wyeth.com

SOURCE: Wyeth
CONTACT: Media Contacts: Qing Xi of Wyeth China,
+021-5252-4633;
or Kylie Park of Wyeth Nutritionals, +1-61-2-8850-8268;
or Kevin Wiggins of Wyeth Pharmaceuticals,
+01-(484)-865-5158;
or Investor Contact: Justin Victoria or Wyeth,
+1-973-660-5340
Web site: http://www.wyeth.com

COPYRIGHT © 2008 - ANTARANEWS

Eularis to address marketing return at measuring marketing ROI

New York and London (ANTARA News/PRNewswire-AsiaNet) - Dr. Andre Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on meeting the challenges of measuring ROI within the changing dynamics of the pharma industry.

On Wednesday 26 March 2008, Dr. Bates will deliver a presentation titled, "Are You Up to the Challenge of Measuring ROI in Changing Dynamics of the Pharma Industry?"

Bates will challenge the thinking of conference attendees and will expose where ROI goes wrong when used to guide current marketing decisions in a changing dynamic market such as pharma. She will also uncover what opportunities are available in this environment, and what can and should be measured for real results when the environment is dynamic.

Bates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis. Under Bates' leadership, Eularis issued three related research reports in the past year, including: Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line (http://www.pharmamarketingroi.com), Pharmaceutical Sales Force Effectiveness Metrics: Are You Measuring the Wrong Things? (http://www.pharmaindustrysfe.com), and Ensuring Profitable Patient Adherence Programs by Effectively Using Analytics to Release the Hidden Value Available to the Bottom Line from Adherence (http://www.patientadherenceroi.com).

The conference will be focused on answering three pivotal areas: "Addressing the Challenges in Measuring ROI," "Ensuring the Sales and Marketing Functions are Aligned" and "Leveraging Your Brand Potential."

To arrange an interview with Eularis http://www.eularis.com, please contact Tracey Haefele at +1 646 673 8408 or via email THaefele@Eularis.com.

About Eularis

Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Eularis' proprietary 94.8 Analytics Process is based on the current market situation.

This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance.

Eularis offers pre-launch analytics, marketing mix modeling, portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions. Eularis has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

For more information about Eularis, visit http://www.eularis.com.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com

SOURCE: Eularis
CONTACT: Tracey Haefele of Eularis, +1-646-673-8408,
THaefele@eularis.com
Web site: http://www.eularis.com

COPYRIGHT © 2008 - ANTARANEWS

Wyeth to Invest $280 Million to Build State-of-the-Art Nutritional Manufacturing Facility in China

Madison, N.J. and Suzhou (ANTARA/PRNewswire-AsiaNet) - Wyeth (NYSE: WYE) announced today that it is investing $280 million to build a state-of-the-art nutritional manufacturing facility in Suzhou Industrial Park, Jiangsu Province, China. The new facility will primarily produce infant formula milk powder and other nutritional products. When completed, the site will be one of the world's largest nutritional manufacturing facilities.

"This investment reflects Wyeth's long-term commitment to pediatric nutrition, as well as the recognition that China is now the fastest-growing market for Wyeth's worldwide nutritional business. When completed, this facility will enable us to meet the growing demand for nutritional products in the Chinese market," said Robert Essner, Wyeth's Chairman of the Board. "A key element of our Company's mission is ensuring that infants and children have access to the best and highest-quality products. This site will help us achieve this objective."

The new facility will become part of Wyeth's global nutritional manufacturing and supply network and will feature state-of-the-art technology for manufacturing milk powder for infants and young children.

Construction at the site started this month, and the plant is scheduled to be operational by late 2010. At full operation, the plant is expected to employ about 500 employees. Products made at this facility will primarily supply the local market.

About Wyeth Pharmaceuticals
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products, including with respect to our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS." The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

For more information, visit www.Wyeth.com

SOURCE Wyeth

CONTACT: Media Contacts: Qing Xi of Wyeth China,
+021-5252-4633; or
Kylie Park of Wyeth Nutritionals,
+1-61-2-8850-8268;
or Kevin Wiggins of Wyeth Pharmaceuticals,
+01-(484)-865-5158; or
Investor Contact: Justin Victoria or Wyeth,
+1-973-660-5340

Web site: http://www.wyeth.com

COPYRIGHT © 2008 - ANTARANEWS

HUYA Bioscience announces clinical trial milestones in China

San Francisco, (ANTARA News/PRNewswire-AsiaNet) - IBC Conference -- HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the completion of three Phase I clinical trial protocols in China of a promising anti-arrhythmic compound, HBI-3000 (Sulcardine sulphate). The data from the trials support a desirable safety profile at dose levels displaying indications of pharmacologic activity. HBI-3000 is being developed as a potential treatment for both atrial and ventricular arrhythmias.

Anti-arrhythmic drugs are used today to treat patients with atrial fibrillation (AF), a serious condition that afflicts 5.6 million Americans. Anti-arrhythmic agents have also been used for the treatment of ventricular arrhythmias, although most have failed to demonstrate a survival advantage, and in some cases carry significant safety risk.

The main concern with anti-arrhythmic drugs is an increased risk of sudden death (Torsade de Pointes) in patients with underlying organic heart disease such as coronary artery disease, prior history of myocardial infarction and heart failure. A large subset of individuals with atrial and ventricular arrhythmias suffers from these conditions, precluding treatment with most existing anti-arrhythmic drugs. Development of safe anti-arrhythmic agents for use in these patients is needed. Pre-clinical data developed by HUYA and its Chinese partner, along with the Chinese clinical trial data suggest that HBI-3000 may have safety advantages over other anti-AF agents and exhibits broad spectrum ion channel inhibition without pro-arrhythmic activity that suggests it may also be safer to use in treatment of ventricular arrhythmias.

According to Mireille Gingras, Ph.D., CEO of HUYA, "the progress on this exciting new compound validates the efficiency and effectiveness of our co-development model with our Chinese partners. With HBI-3000, for example, we will have the opportunity to collaborate with our Chinese partners on their Phase II trials, which will be valuable in the U.S. development process. We leverage the knowledge and experience of both teams -- in addition to existing Phase I data from China -- to streamline and optimize that process in both countries. Our model sets a new standard for integrated, China/U.S. pharmaceutical co-development."

HUYA's innovative co-development model

HUYA was one of the first companies to recognize the potential of China as a source for novel pre-clinical and clinical stage compounds and pioneered an innovative co-development model. HUYA partners with Chinese research institutions and pharmaceutical companies to leverage and extend their research efforts, accelerate development, and provide a bridge into the U.S. development process and the biopharma market.

This model contrasts with that of large pharmaceutical companies whose approach is to start their own research facilities in China hoping to tap its large biotech talent pool, or that of smaller competitors with "one-off" single compound strategies. With three strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA is uniquely positioned to identify and license novel Chinese compounds. Moreover, the strength of its relationships with its Chinese partners ensures a continuous source of these compounds for the future.

One of the key differentiators of HUYA's approach is the assembly of a world-class team of scientific and clinical advisors for each promising new compound, such as HBI-3000. This team collaborates with its Chinese partners and is then able to leverage and extend these efforts as the compounds enter the development process in the U.S, speeding the process and mitigating risk.

The U.S. advisors (announced in a separate release) for HBI-3000 comprise a world class team of scientists and clinicians including Benedict Lucchesi, Ph.D. MD, Peter R. Kowey, M.D., Dennis Roy, M.D., Jefferson L. Anderson, M.D., Eric J. Topol, M.D., and Stanley Nattel, M.D.

About HUYA

HUYA is the leader in U.S./China pharmaceutical co-development, formed to meet the global need for new, untapped sources of pre-clinical and clinical stage compounds. HUYA identifies the most promising new compounds in China and partners with Chinese research institutions to leverage and extend their research efforts, accelerate development, and provide a bridge into the U.S. development process and the biopharma market. With three strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA has pioneered the most innovative and productive approach for pharmaceutical co-development between the U.S and China. Further information about the company is available at www.huyabio.com.

Contact:
USA:
Jan Tuttleman, Ph.D.
Vice President, Marketing
HUYA Bioscience International
(858) 798-8800
jtuttleman@huyabio.com
China:
Wen Chen, M.S., MBA
EVP China Operation and Chief Representative
HUYA Bioscience International
86 (21) 51323312
wchen@huyabio.com
Media Contacts:
Amy Berry
(415) 793-2258
amyeberry@comcast.net
Juliet Travis
(510) 452-3771
juliet@travispr.com

SOURCE: HUYA Bioscience International

EDITORS NOTE: HUYA CEO Mireille Gingras, Ph.D., will be available for interviews at the IBC Conference, March 3-4 in San Francisco

CONTACT: USA, Jan Tuttleman, Ph.D., Vice President, Marketing, +1-858-798-8800, jtuttleman@huyabio.com, or China, Wen Chen, M.S., MBA, EVP China Operation and Chief
Representative, +862151323312, wchn@huyabio.com, both of HUYA Bioscience International; or Media, Amy Berry, +1-415-793-2258, amyeberry@comcast.net, or Juliet Travis, +1-510-452-3771, juliet@travispr.com/

WEB SITE: http://www.huyabio.com

COPYRIGHT © 2008 - ANTARANEWS